Print Page  |  Close Window

2014 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
04/01/14Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 1, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and T... 
Printer Friendly Version
03/31/14LabCorp Announces Changes to Board of Directors
Wendy E. Lane, Arthur H. Rubenstein and M. Keith Weikel to Retire from Board of Directors at the End of Their Current Terms; D. Gary Gilliland Named to the Board of Directors Effective April 1, 2014 BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 31, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Drs. Arthur H. Rubenstein and M. Keith Weikel will retire from the Board at the conclu... 
Printer Friendly Version
03/25/14LabCorp Announces Appointment of Chief Financial Officer
Glenn A. Eisenberg Appointed as Executive Vice President and Chief Financial Officer Effective June 16, 2014 BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 25, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the appointment of Glenn A. Eisenberg as Executive Vice President and Chief Financial Officer, effective June 16, 2014. Brad Hayes will continue in his role as Chief Financial Officer through the tr... 
Printer Friendly Version
03/11/14LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2014 to September 11, 2014, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
03/04/14LabCorp is Scheduled to Present at the Barclays Capital 2014 Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 4, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Barclays Capital 2014 Global Healthcare Conference in Miami Beach, FL. LabCorp’s presentation is planned for Tuesday, March 11, 2014 at 10:45 AM (Eastern Time). A live audio webcast of the presentation will be available via the ... 
Printer Friendly Version
02/24/14LabCorp Announces the Availability of Thermo Scientific ImmunoCAP™ Allergy Testing Products
BURLINGTON, N.C.--(BUSINESS WIRE)--Feb. 24, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of Thermo Scientific ImmunoCAP™ allergy testing products from Thermo Fisher Scientific, Inc. (NYSE: TMO). Allergies affect approximately 60 million individuals within the U.S. and this population is growing. In addition to the more commonly associated symptoms of allergies such as sneezing, c... 
Printer Friendly Version
02/07/14Laboratory Corporation of America® Holdings Announces 2013 Fourth Quarter and Full Year Results and Provides 2014 Guidance
GAAP Diluted EPS of $1.43 and $6.25 for the Quarter and the Year, respectively Non-GAAP Adjusted EPS Excluding Amortization of $1.61 and $6.95 for the Quarter and the Year, respectively (negative impact from weather was $0.03 and $0.07, respectively) 2013 Operating Cash Flow of $818.7 Million and Free Cash Flow of $616.5 Million 2013 Share Repurchase of approximately $1.0 Billion, repre... 
Printer Friendly Version
01/13/14LabCorp to Offer New FDA approved Breast Cancer Prognostic Test
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 13, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the launch of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay, an FDA approved breast cancer prognostic gene signature assay developed by NanoString Technologies, Inc. Prosigna provides a risk category and a numerical score to assess the probability of breast cancer recurrence in certain female breast can... 
Printer Friendly Version
01/06/14LabCorp is Scheduled to Present at the 32nd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 6, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. LabCorp’s presentation is planned for Tuesday, January 14, 2014 at 4:00 p.m. (PST). A live audio webcast of the presentation will be available via the Compa... 
Printer Friendly Version
01/02/14Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006, between LabCorp and T... 
Printer Friendly Version